Lacidipine-13C8

Lacidipine-13C8 is the deuterium labeled Lacidipine[1]. Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI) [2][3].

Product Specifications

CAS Number

[1261432-01-2]

UNSPSC

12352005

Target

Apoptosis; Calcium Channel; Caspase; Reactive Oxygen Species (ROS)

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB

Applications

Neuroscience-Neurodegeneration

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/lacidipine-13c8.html

Solubility

10 mM in DMSO

Smiles

CCO[13C]([13C]1=[13C](N[13C]([13CH3])=[13C](C1C2=C(/C=C/C(OC(C)(C)C)=O)C=CC=C2)[13C](OCC)=O)[13CH3])=O

Molecular Formula

C18 13C8H33NO6

Molecular Weight

463.48

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Zhang A, et al. Lacidipine attenuates apoptosis via a caspase-3 dependent pathway in human kidney cells. Cell Physiol Biochem. 2013;32 (4) :1040-9. |[3]Cristofori P, et al. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens. 2000 Oct;18 (10) :1429-36.